The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
Drug repurposing expands the therapeutic applications of existing medications, while repositioning examines drugs that never reached market. In neurodegeneration, the approach is described as a pragmatic shortcut into mid- to late-stage trials.
The United Arab Emirates has unveiled two gene therapy projects targeting autism, epilepsy, and rare brain disorders in children. The initiatives focus on underlying genetic causes and earlier diagnosis.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Fujifilm Biotechnologies has opened the UK's largest single-use biopharmaceutical CDMO facility in Teesside with a £400 million investment. The 110,000 sq ft facility features 19,000 liters of bioreactor capacity and will be operational in H1 2026. The expansion includes a new Bioprocess Innovation Centre that doubles the site's lab footprint.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Creative Biolabs has expanded its preclinical research capabilities with an upgraded rodent behavioral profiling platform for CNS drug discovery and enhanced circRNA and nucleic acid analysis platforms for gene therapy development.
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07545473 |
Retinal Hyperspectral Imaging in Neurodegenerative Diseases |
RECRUITING | NA |
| NCT07514520 |
Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION |
ACTIVE_NOT_RECRUITING | |
| NCT07489898 |
Novel Technologies to Measure Vision-related Quality of Life |
NOT_YET_RECRUITING | |
| NCT07470710 |
Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07324330 |
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity |
RECRUITING | NA |
| NCT07268079 |
Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality |
RECRUITING | |
| NCT07232147 |
Clinical Research on Stem Cell Therapy for Parkinson's Disease |
NOT_YET_RECRUITING | PHASE1 |
| NCT07118137 |
Memory Deterioration in Alzheimer Disease |
RECRUITING | |
| NCT06993142 |
Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage |
NOT_YET_RECRUITING | NA |
| NCT06965816 |
Using Neuroimaging to Early Diagnose Alzheimer's Disease Through Hippocampal Atrophy Assessment |
COMPLETED |
